These are the stocks posting the largest moves before the bell.Market Insiderread more
CNBC's Mike Santoli breaks down the aggressive buying of "sure things" and shunning of cyclical and policy risk.Trading Nationread more
The Iranian Intelligence Ministry held a briefing on Monday where they announced the alleged spies were Iranian citizens but trained by the CIA.World Newsread more
Equifax will pay at least $575 million, and potentially as much as $700 million, to settle allegations over its massive over 2017 data breach, U.S. regulators said in a...Technologyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
Two traders say Boeing's on the path to recovery.Trading Nationread more
Bridgewater Associates's flagship fund reportedly posted one of its worst first-half performances in two decades.Hedge Fundsread more
The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Shares of Micron rose on Monday following an upgrade to buy from neutral from Goldman Sachs, citing a faster-than-expected deceleration in memory chip production.Investingread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
PayPal: "Here's the thing that you need to know: this stock has now dropped 5 straight points. Another 2 points and it's really going to be oversold and then, and only then, would I pull the trigger."
Senseonics: "If you're going to do glucose monitoring, if you want to be conservative, you buy Abbott. If you want to be a little more aggressive, you buy Dexcom. Those are the only two that I really care about. "
Idexx Laboratories: "Idexx Labs is the kind of stock that does come down here and that is exactly when you buy it. Another [$]5 [and] I think it's perfect."
Sonos: "No, no, no, no. That's not the kind of stock you buy into weakness. That is not the kind of stock that is going to bounce right back. That is the kind of stock that has very inconsistent numbers. Let's stay away. Don't buy."
Denbury Resources: "I think you've had a really good run in that one. It's not a really high-quality company. That group is struggling. I'd say ring the register."
Apptio: "To me, this is a worrisome situation because I've got cloud stocks that are going down and I want to buy the cloud kings when they go down. Salesforce is going down– I mean, congratulations, Marc and Lynne Benioff. Buying Time Magazine, I think, is good and it's totally separate from Salesforce. But Salesforce is going down. I'd rather see you in some high-quality stock like that. "
Invitae: "I have looked at this company when I did the Biotech Bible for TheStreet.com and I felt that it was way too speculative. But you know what? This thing has just roared. But it's not mine. It's too speculative for me. As long as you understand that it is a spec, then you're OK."
Wayfair: "You know, this is one that I'm going to tell you I'm not the call on. I really liked it. I thought it would go higher. I never thought it would get to this level. At these prices, I think it's too high, but why listen to me? I actually was saying that for the last 20 points."
JD.com: "That is way too speculative and I am not a believer in Chinese stocks. There isn't a single one that I'm recommending. There. That's it."
Disclosure: Cramer's charitable trust owns shares of PayPal, Abbott Laboratories, Salesforce.com and Microsoft.